ClinicalTrials.gg
RecruitingNCT05246813Updated Mar 25, 2026

Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)

An observational study in Osteoporosis, Osteoarthritis, Hip and Hip Fractures, sponsored by Imelda Hospital, Bonheiden. Recruiting at 1 site in Belgium. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Imelda Hospital, Bonheiden · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
24
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.

Started
2022
with 1 other
Observational
5 of 32
2 open now
Registered
30th of 32
by date

Among the 32 studies in Osteoporosis with a site in Belgium, this one is one of 2 that started in 2022, is one of 5 observational ones, and was the 30th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Osteoporosis with a site in Belgium, or all of them as a file.
02

Study summary

Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.

03

Conditions studied

  • Osteoporosis
  • Osteoarthritis, Hip
  • Hip Fractures
  • Clonal Hematopoiesis of Indeterminate Potential
  • Aging
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing hip arthroplasty for hip osteoarthritis or osteoporotic hip fractures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years and older

Exclusion criteria

Exclusion Criteria:

  • known haematological condition (myelodysplasia, leukemia, cancer)
  • inability to provide written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Osteoporotic hip fracture patients

    Other: Blood and bone marrow cell collection

  • Hip osteoarthritis patients

    Other: Blood and bone marrow cell collection

Interventions

  • OtherBlood and bone marrow cell collection

    Collection of blood and bone marrow

06

What researchers measure

Primary outcomes

  1. Gene Set Enrichment Analysis (GSEA) Normalized Enrichment Score (NES)

    Time frame: One day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2028, 82 months after the start.

Of 115 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 82 months is above that.

Counting every sponsor, half of 126 studies reached it within 51 months; a quarter within 24 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Feb 18, 2022
StartActual
Feb 11, 2022
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05246813
Lead sponsor
Imelda Hospital, Bonheiden
Responsible party
Michaël R Laurent, MD PhD (Principal Investigator, Imelda Hospital, Bonheiden) — Principal investigator
First posted
Feb 18, 2022
Start date
Feb 11, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 25, 2026

Study contacts

Michaël R. Laurent, MD PhD
Contact
michael.laurent@imelda.be
+32485143267
Nick Van Gastel, PhD
principal investigator · de Duve Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion